VANCOUVER, May 29 /PRNewswire-FirstCall/ -- QLT Inc. ( Nachrichten ) (NASDAQ: QLTI; TSX: QLT) announced today that QLT USA, Inc. submitted a labeling supplement (sNDA) for Aczone(TM) to the U.S. Food and Drug Administration (FDA) to request the removal of the gluceose-6-phosphate dehydrogenase (G6PD) screening and blood monitoring requirements from its current label.
From: www.finanznachrichten.de
TM) labeling supplement for removal of blood screening requirement
Posted by Ruslan Abuzant at 11:31 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment